Aim: The cost–effectiveness of treatment options (anticholinergics, β3-adrenoceptor agonists,
onabotulinumtoxinA, sacral nerve stimulation and percutaneous tibial stimulation [the latter two
including new rechargeable neurostimulators]) for the management of overactive bladder (OAB) were
compared with best supportive care (BSC) using a previously published Markov model. Materials &
methods: Cost–effectiveness was evaluated over a 15-year time horizon, and sensitivity analyses were
performed using 2- and 5-year horizons. Discontinuation rates, resource utilization, and costs were
derived from published sources. Results: UsingMedicare and commercial costs over a 15-year time period,
onabotulinumtoxinA 100U had incremental cost–effectiveness ratios (ICERs) gained of $39,591/qualityadjusted
life-year (QALY) and $42,255/QALY, respectively, versus BSC, which were the lowest ICERs of all
assessed treatments. The sensitivity analyses at 2- and 5-year horizons also showed onabotulinumtoxinA
to be the most cost-effective of all assessed treatments versu
Funding
The design, study conduct and financial support for the study were provided by Allergan (prior to acquisition by AbbVie). AbbVie participated in the interpretation of data, review and approval of the publication. B Murray has served as a consultant and investigator for Allergan, an AbbVie company, and as a consultant for Astellas, Urovant and Medtronic; J Miles-Thomas has served as a consultant for Allergan, an AbbVie company, and Urovant, and as a speaker for Allergan, an AbbVie company, Astellas and Urovant; AJ Park has served as a speaker for Allergan, an AbbVie company, and received royalties from UptoDate; VW Nitti has served as an investigator for Allergan, an AbbVie company, Astellas and Cook MyoSite; CJ Chermansky has served as an investigator for Allergan, an AbbVie company, and for Cook MyoSite; VB Nguyen is a consultant for Allergan, an AbbVie company; A Tung, P Gillard and A Lalla are employees of Allergan, an AbbVie company. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. S Murray and JL Giel of Evidence Scientific Solutions (PA, USA) provided medical writing and editing services in the development of this manuscript. AbbVie provided funding to Evidence Scientific Solutions for this work.
